# EDGAR Filing Document

**Accession Number:** 0001712369
**File Stem:** 0001712369-26-000006
**Filing Date:** 2026-6
**Character Count:** 7732
**Document Hash:** 7f8587fde12d68b491988284667f34f0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001712369-26-000006.hdr.sgml**: 20260623

**ACCESSION NUMBER**: 0001712369-26-000006

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20260617

**FILED AS OF DATE**: 20260623

**DATE AS OF CHANGE**: 20260623

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Slaoui Moncef
- **CENTRAL INDEX KEY:** 0001712369

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39323
- **FILM NUMBER:** 261111274

**MAIL ADDRESS:**
- **STREET 1:** C/O INTELLIA THERAPEUTICS, INC.
- **STREET 2:** 40 ERIE STREET SUITE 130
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Vaxcyte, Inc.
- **CENTRAL INDEX KEY:** 0001649094
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 464233385
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 825 INDUSTRIAL ROAD, STE. 300
- **CITY:** SAN CARLOS
- **STATE:** CA
- **ZIP:** 94070
- **BUSINESS PHONE:** 650-837-0111

**MAIL ADDRESS:**
- **STREET 1:** 825 INDUSTRIAL ROAD, STE. 300
- **CITY:** SAN CARLOS
- **STATE:** CA
- **ZIP:** 94070

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SutroVax, Inc.
- **DATE OF NAME CHANGE:** 20150724

## Ex-24

![](poasection16filings-slao001.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;825 Industrial Road, Suite 300 San Carlos, California 94070 USA vaxcyte.com POWER OF ATTORNEY KNOW ALL BY THESE PRESENTS that the undersigned hereby cons tutes and appoints each of Andrew Guggenhime, Mikhail Eydelman, Elvia Cowan, Robert Bitman and Peter Efremenko, representa ves of Vaxcyte, Inc. (the "Company"), as well as Raquel Fox and Jeongu Gim, legal professionals of Skadden, Arps, Slate, Meagher & Flom LLP, legal counsel to the Company ("Skadden"), signing individually, as the undersigned's true and lawful a orneys-in-fact and agents to: 1. execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director and/or more than 10% stockholder of the Company, Forms 3, 4 and 5 in accordance with Sec on 16(a) of the Securi es Exchange Act of 1934 and the rules thereunder; 2. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Forms 3, 4 or 5, complete and execute any amendment or amendments thereto, and mely file such form with the U.S. Securi es and Exchange Commission and any stock exchange or similar authority; and 3. take any other ac on of any type whatsoever in connec on with the foregoing which, in the opinion of such a orney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such a orney-in-fact on behalf of the undersigned pursuant to this Power of A orney shall be in such form and shall contain such terms and condi ons as such a orney-in-fact may approve in such a orney-in-fact's discre on. The undersigned hereby grants to each such a orney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted (the "Purpose"), as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of subs tu on or revoca on, hereby ra fying and confirming all that such a orney-in-fact, or such a orney-in-fact's subs tute or subs tutes, shall lawfully do or cause to be done by virtue of this Power of A orney and the rights and powers herein granted. The undersigned acknowledges that the foregoing a orneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibili es to comply with Sec on 16 of the Securi es Exchange Act of 1934. This Power of A orney supersedes any and all powers of a orney granted by the undersigned for the same or substan ally similar Purpose and shall remain in full force and effect un l the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transac ons in securi es issued by the Company, (b) revoca on by the undersigned in a signed wri ng delivered to the foregoing a orneys-in-fact or (c) as to any a orney-in-fact individually, un l such a orney- in-fact is no longer employed by the Company or Skadden. IN WITNESS WHEREOF, the undersigned has caused this Power of A orney to be executed as of this 19th day of June, 2026. /s/ Moncef Slaoui ________________________________ Moncef Slaoui

------

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Slaoui Moncef<br><sub>(Last) (First) (Middle)</sub><br>C/O VAXCYTE, INC.<br>825 INDUSTRIAL ROAD, SUITE 300<br><sub>(Street)</sub><br>SAN CARLOS, CA 94070<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Vaxcyte, Inc. [ PCVX ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-06-17 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director   [ ] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| No securities owned. | 0 | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |

---

**Signature:** Moncef Slaoui, by /s/ Peter N. Efremenko, Attorney-In-Fact  
**Date:** 2026-06-23

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**